Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Kura Oncology, Inc.

Get SEC filing alerts via email and in your feed for Kura Oncology, Inc.

KURA

Kura Oncology, Inc.

About Kura Oncology, Inc.

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing precision cancer therapies. Its pipeline includes small molecule inhibitors targeting genetic and molecular pathways in cancers such as AML, ALL, GIST, and solid tumors. The company emphasizes pairing therapeutics with diagnostics for patient-specific treatment, leveraging translational research, and strategic collaborations to advance targeted, potentially more effective and safer cancer treatments.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Kura Oncology, Inc.

1
1
Kura Oncology, Inc. Kura Oncology Reports $18.3 Million Revenue in Q1 2026, Net Loss Increases to $73.3 Million

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Kura Oncology, Inc. Kura Oncology Reports FDA Approval of KOMZIFTI and $2.1 Million in Product Revenue for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Kura Oncology, Inc. Kura Oncology Reports $20.8 Million Collaboration Revenue and $74.1 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Kura Oncology, Inc. Kura Oncology Reports $15.3 Million Collaboration Revenue and $66.1 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Kura Oncology, Inc. Kura Oncology Reports $53.9 Million Collaboration Revenue and Expands Clinical Pipeline

Via official filing (AI summary) | over 1 year ago | 0 comments

6
1
Kura Oncology, Inc. Kura Oncology Reports Financial Results for Q3 2024, Net Loss of $54.4 Million

Via official filing (AI summary) | over 1 year ago | 0 comments